Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Benschop RJ, Chow CK, Tian Y, Nelson J, Barmettler B, Atwell S, Clawson D, Chai Q, Jones B, Fitchett J, Torgerson S, Ji Y, Bina H, Hu N, Ghanem M, Manetta J, Wroblewski VJ, Lu J, Allan BW.
Benschop RJ, et al. Among authors: nelson j.
MAbs. 2019 Aug/Sep;11(6):1175-1190. doi: 10.1080/19420862.2019.1624463. Epub 2019 Jun 10.
MAbs. 2019.
PMID: 31181988
Free PMC article.